Table 2. Effects of patient characteristics on the relative dose intensities (RDIs) of each agent.
| L-OHP ≥ 70% | CPT-11 ≥ 75% | 5-FU bolus > 0% | 5-FU ci. ≥ 80% | |||||
|---|---|---|---|---|---|---|---|---|
| Factors (Reference) levels | Odds Ratio (95% CI) | p | Odds Ratio (95% CI) | p | Odds Ratio (95% CI) | p | Odds Ratio (95% CI) | p |
| Sex (Male) Female |
2.36 (1.35, 4.26) | <0.005 | 1.53 (0.93, 2.54) | 0.094 | ||||
| Age (<65) ≧65 |
||||||||
| Disease status (LA) Metastatic Recurrence |
2.00 (1.14, 3.52) 1.20 (0.61, 2.36) |
<0.05 0.600 |
1.67 (0.93–3.05) 0.99 (0.48–2.03) |
0.090 0.972 |
||||
| History of PT (No) Yes |
||||||||
| ECOG PS (0) 1/2 |
0.43 (0.24, 0.73) | <0.005 | ||||||
| UGT1A1(Wild) Single hetero Double hetero |
||||||||
| Albumin, g/dl (<3.5) ≧3.5 |
2.02 (1.11, 3.76) |
<0.05 | 2.20 (1.10, 4.71) |
<0.05 | 2.53 (1,32, 5.07) |
<0.01 | ||
| CRP, mg/dl (<2.0) ≧2.0 |
3.25 (1.46, 7.92) | <0.05 | 2.85 (1.36, 6.13) | <0.01 | 2.67 (1.23, 5.98) | <0.05 | ||
| ID of L-OHP (Orig.) Decreased |
||||||||
| ID of CPT-11 (Orig.) Decreased |
0.30 (0.14, 0.62) | <0.005 | ||||||
| ID of 5-Fu bolus (Orig.) Decreased |
0.26 (0.06, 0.91) |
<0.05 | 2.02 (1.01, 4.30) |
0.056 | 8.41 × 10−24 (0.00–0.00) |
0.999 | 1.44 (0.91, 2.27) |
0.121 |
| ID of 5-Fu ci. (Orig.) Decreased |
1.42 (0.91, 2.22) |
0.121 | 8.82 × 10−8 (NA-8.07 × 10−24) |
0. 981 | ||||
Abbreviations: L-OHP, oxaliplatin; CPT-11, irinotecan; 5-FU, fluorouracil; ci, continuous infusion; CI, confidence interval; LA, locally advanced; PT, prior therapy; ECOG PS, Eastern Cooperative Oncology Group Performance status; CRP, C-reactive protein; ID, initial dose; Orig, original dose; NA, not applicable.